 | This articleneeds additional citations forverification. Please helpimprove this article byadding citations to reliable sources. Unsourced material may be challenged and removed. Find sources: "VM" nerve agent – news ·newspapers ·books ·scholar ·JSTOR(March 2018) (Learn how and when to remove this message) |
 | |
 | |
| Names | |
|---|---|
| Preferred IUPAC name S-[2-(Diethylamino)ethyl]O-ethyl methylphosphonothioate | |
| Identifiers | |
3D model (JSmol) | |
| ChemSpider |
|
| UNII | |
| |
| |
| Properties | |
| C9H22NO2PS | |
| Molar mass | 239.32 g/mol |
Except where otherwise noted, data are given for materials in theirstandard state (at 25 °C [77 °F], 100 kPa). | |
VM (Edemo) is a "V-series"nerve agent closely related to the better-knownVX nerve agent.[1]
Like most of the agents in the V-series (with the exception of VX), VM has not been extensively studied outside ofmilitary science. Little is known about thischemical compound other than itschemical formula.[1]
It is commonly theorized that the so-called "second-generation" V series agents came from aCold War eraRussianchemical weapons development program. They may have been developed sometime between 1950 and 1990. They have similarlethal dose levels to VX (between 10 and 50 mg) and have similarsymptoms andmethod of action to other nerve agents that act oncholinesterase. The treatment remains the same, but the window for effectively treating second generation V seriesseizures is shorter. In addition to the standard seizures, some of the second generation V series agents are known to causecomas.[1]
{{cite book}}: CS1 maint: DOI inactive as of July 2025 (link) | This article about anorganic compound is astub. You can help Wikipedia byexpanding it. |